MannKind inks new insulin supply contract

|About: MannKind Corporation (MNKD)|By:, SA News Editor

MannKind Corp. (NASDAQ:MNKD) and Amphastar Pharmaceuticals (NASDAQ:AMPH) consummate a Supply Agreement under which Amphastar will manufacture recombinant human insulin for use in Afrezza,

Under the terms of the agreement, MannKind will purchase an aggregate of €120.1M from 2015 - 2019. The agreement term ends on December 31, 2019 but can be renewed in successive two-year terms upon 12 months written notice. MannKind can terminate the agreement upon two-years written notice.